Natural history of HFE simple heterozygosity for C282Y and H63D: A prospective 12-year study
MetadataShow full item record
This is the peer reviewed version of the following article: "Zaloumis, S., Allen, K., Bertalli, N., et al. 2015. Natural history of HFE simple heterozygosity for C282Y and H63D: A prospective 12-year study. Journal of Gastroenterology and Hepatology. 30 (4): pp. 719-725.", which has been published in final form at http://doi.org/10.1111/jgh.12804. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving at http://olabout.wiley.com/WileyCDA/Section/id-820227.html#terms
Background and Aim - The risk of hemochromatosis-related morbidity for HFE simple heterozygosity for either the C282Y or H63D substitutions in the HFE protein was assessed using a prospective community-based cohort study. Methods - HFE genotypes were measured for 31 192 persons of northern European descent, aged between 40 and 69 years when recruited to the Melbourne Collaborative Cohort Study, and subjects were followed for an average of 12 years. For a random sample of 1438 participants stratified according to HFE genotype, two sets of biochemical iron indices performed 12 years apart and, at follow-up only, the presence/absence of six disease features associated with hereditary hemochromatosis were obtained. Summary data for 257 (139 female) C282Y simple heterozygotes and 123 (74 female) H63D simple heterozygotes were compared with 330 (181 female) controls with neither HFE mutation. Results - At baseline, mean transferrin saturation (TS) (95% confidence interval) and prevalence of TS > 55% were 35.14% (33.25, 37.04) and 3/112 (3%), 33.03% (29.9, 36.15) and 0/39 (0%), and 29.67% (27.93, 31.4) and 3/135 (2%) for C282Y, H63D and wild-type male participants, respectively. At follow-up, mean TS levels remained similar to baseline levels for both men and women irrespective of simple heterozygosity for either mutation. No HFE C282Y or H63D simple heterozygotes had documented iron overload (based on hepatic iron measures or serum ferritin greater than 1000 mg/L at baseline with documented therapeutic venesection). Conclusion - No documented iron overload was observed for HFE simple heterozygotes for either C282Y or H63D, and morbidity for both HFE simple heterozygote groups was similar to that of HFE wild-type participants.
Showing items related by title, author, creator and subject.
HFE p.C282Y homozygosity predisposes to rapid serum ferritin rise after menopause: A genotype-stratified cohort study of hemochromatosis in Australian womenWarne, C.; Zaloumis, S.; Bertalli, N.; Delatycki, M.; Nicoll, A.; McLaren, C.; Hopper, J.; Giles, G.; Anderson, G.; Olynyk, John; Powell, L.; Allen, K.; Gurrin, L.; Bahlo, M.; Fletcher, A.; Forrest, S.; Osborne, N.; Vulpe, C.; Turkovic, L. (2017)Background and Aim: Women who are homozygous for the p.C282Y mutation in the HFE gene are at much lower risk of iron overload-related disease than p.C282Y homozygous men, presumably because of the iron-depleting effects ...
Therapeutic venesection at the Australian Red Cross Blood Service: Impact of the High Ferritin Application on management of hereditary haemochromatosisBentley, P.; Bell, B.; Olynyk, John (2015)© The Royal Australian College of General practitioners 2015. Background Therapeutic venesection is an established treatment for hereditary haemochromatosis. The C282Y homozygotes and C282Y/H63D compound heterozygotes are ...
Characterization of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysisHolman, R.; Olynyk, John; Kulkarni, H.; Ferrari, P. (2017)Background: Parenteral iron is integral in the treatment of anaemia of chronic kidney disease patients on haemodialysis (HD). However, increased liver iron concentration (LIC) can result from such treatment, and this ...